Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks

References

• Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007 Nov;25(6):535–546.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014 Aug 17;20(8):13030/qt48r4w8h2.
   Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015 Jun;72(6):961–7 e5.
   PubMed Web of Science ®Google Scholar
• Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int. 2016 May;36(5):603–612.
   PubMed Web of Science ®Google Scholar
• Bai F, Li GG, Liu Q, et al. Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.
   PubMed Web of Science ®Google Scholar
• Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020 Oct 11;21(20):7488.
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015 Jul;21(7):719–729.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017 Mar;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018 Jan;178(1):114–123.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J DermatolTreat. 2022 Jul 13;33(2):848–856.
   Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study. Am J Clin Dermatol. 2020 Dec;21(6):881–890.
   PubMed Web of Science ®Google Scholar
• Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 Dec;185(6):1146–1159.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022 Nov 17;86(4):827–834.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Bernardini N, et al. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opin Biol Ther. 2022 Jun 22;22(12):1585–1592.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020 Jul 9;9(7):2170.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, et al. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J DermatolTreat. 2022 Feb 7;33(5):2560–2564.
   Google Scholar
• Megna M, Potestio L, Fabbrocini G, et al. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205–212.
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Viviani F, Merli Y, et al. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience. Expert Opin Biol Ther. 2022 Apr 13;22(12):1561–1566.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023 Jan 25. DOI:10.1111/jdv.18913.
   Web of Science ®Google Scholar
• European Medicines Agency. Guselkumab, summary of product characteristics. [3 Mar 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
   Google Scholar
• Ministero della Salute. Attività dei Comitati Etici istituiti ai sensi del decreto ministeriale 18 marzo 1998. 2002. [cited 2023 3 Mar]. Available from: https://www.aifa.gov.it/documents/20142/0/Cir_Min_2_Settembre_2002_CE.pdf
   Google Scholar
• Megna M, Fabbrocini G, Cinelli E, et al. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J DermatolTreat. 2022 Mar;33(2):1074–1078.
   Google Scholar
• Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr;82(4):936–945.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocini G, Cinelli E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021 Jan;34(1):e14673.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Zaaroura H, Mufti A, et al. Drug survival of guselkumab in patients with plaque psoriasis: a 2 year retrospective, multicenter study. JAAD Int. 2021 Sep;4:49–51.
   PubMedGoogle Scholar
• Lee EB, Reynolds KA, Pithadia DJ, et al. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. J DermatolTreat. 2020 Jun;31(4):342–343.
   Google Scholar
• Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022 Oct 1;158(10):1131–1141.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021 Jul;22(4):567–579.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019 May;180(5):1039–1049.
   PubMed Web of Science ®Google Scholar